Resetting baroreceptors to a lower arterial pressure level by enalapril avoids baroreflex mediated activation of sympathetic nervous system by nifedipine

Life Sciences

Volumn 68, Issue 25, 2001, Pages 2769-2779

  Zhang, Weiguo ^a,c   Wang, Zhongyun ^b  

^a FUWAI HOSPITAL   (China)

^b LITCM   (China)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Angiotensin converting enzyme inhibitor (ACEI); Baroreceptor reflex; Baroreceptor resetting; Calcium channel blocker (CCB); Hypertension; Spontaneously hypertensive rats (SHR); Sympathetic nervous system (SNS)

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CATECHOLAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; NIFEDIPINE;

ADRENERGIC ACTIVITY; ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ARTICLE; CATECHOLAMINE BLOOD LEVEL; CONTROLLED STUDY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRESSORECEPTOR REFLEX; RAT; TACHYCARDIA;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DRUG INTERACTIONS; ENALAPRIL; EPINEPHRINE; HYPERTENSION; MALE; NIFEDIPINE; NOREPINEPHRINE; PRESSORECEPTORS; RATS; RATS, INBRED SHR; RATS, WISTAR; SYMPATHETIC NERVOUS SYSTEM; TACHYCARDIA; TIME FACTORS;

EID: 0035843965     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(01)01078-5     Document Type: Article

References (38)

1. van Zwieten PA. Calcium entry blockers (calcium antagonists). In: Van Zwieten PA, editor. Handbook of HyPertension. Amsterdam: Elsevier, 1984, pp. 331-42.
2. Hansson L. Calcium antagonists: An overview. Am Heart J 1991;122:308-11.
3. Lender D, Arauz-Pacheco C, Breen L, Mora-Mora P, Ramirez LC, Raskin P. A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. Am J Hypertens 1999; 12:298-303.
4. Zanchi A, Brunner HR, Waeber B, Burnier M. Renal haemodynamic and protective effects of calcium antagonists in hypertension. J Hypertens 1995;13:1363-75.
5. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, HEcker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the international nifedipine trial on antiatherosclerotic therapy (INTACT). Lancet 1990;335:1109-13.
6. Hof RP, Tapparelli C, Weinstein DB. Hemodynamic, antivasoconstrictor, and antiatherosclerotic effects of calcium antagonists in animal models of atherosclerosis. J Cardiovasc Pharmacol 1990;15:S7-12.
7. Zanchetti A. Antiatherosclerotic effects of antihypertensive drugs: Recent evidence and ongoing trials. Clin Exp Hypertens 1996;18:489-99.
8. Waters D, Lesperance J, Francetich M, et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990;82:1940-53.
9. Messerli FH, Grossman E. The calcium antagonist controversy: A posthumous commentary. Am J Cardiol 1998;82:35R-9R.
10. Epstein M. The calcium antagonist controversy: The emerging importance of drug formulation as a determinant of risk. Am J Cardiol 1997;79:9-19.
11. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989;79:733-43.
12. Cooke HM, Lynch A. Biorhythms and chronotherapy in cardiovascular disease. Am J Hosp Pharm 1994;51: 2569-80.
13. Zhang W. Can we use calcium antagonist better in antihypertensive therapy? Circadian consideration. PharMacol Res 1996;34:187-91.
14. Zanchetti A, Chalmers JP, Arakawa K, et al. The 1993 Guidelines for the Management of Mild Hypertension: Memorandum from a WHO/ISH Meeting. Blood Press 1993;2:86-100.
15. Luscher TF, Waeber B. Efficacy and safety of various combination therapies based on a calcium antagonist in essential hypertension: Results of a placebo-controlled randomized trial. J Cardiovasc Pharmacol 1993;21: 305-9.
16. Anonym. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VI). NIH Publication 1998:3-64.
17. Salgado HC, Krieger EM. Extent of baroreceptor resetting in response to sodium nitroprusside and verapamil. Hypertension 1988;11:I121-5.
18. de Abreu GR, Salgado HC. Antihypertensive drugs distinctly modulate the rapid resetting of the baroreceptors. Hypertension 1990;15:I63-7.
19. Xavier-Neto J, Moreira ED, Krieger EM. Viscoelastic mechanisms of aortic baroreceptor resetting to hypotension and to hypertension. Am J Physiol 1996;271:H1407-15.
20. Zhang W, Liu L, Zheng D, et al. Effects of atrial natriuretic factor on patients with renovascular hypertension. Chin Med J 1992;105:732-7.
21. Zhang W, Pettersson A, Thoren P, Hedner T. Effects of 1,1-dimethylguanidine administration on blood pressure, heart rate and renal sympathetic nerve activity in normotensive and spontaneously hypertensive rats. Acta Physiol Scand 1997;159:1-6.
22. Zhang W, Thoren P. Hyper-responsiveness of adrenal sympathetic nerve activity in spontaneously hypertensive rats to ganglionic blockade, mental stress and neuronglucopenia. Pflugers Arch - Eur J Phsiol 1998; 437:56-60.
23. Packer M. Calcium channel blockers in chronic heart failure. The risks of "physiologically rational" therapy. Circulation 1990;82:2254-7.
24. Lindqvist M, Kahan T, Melcher A, Hjemdahl P. Acute and chronic calcium antagonist treatment elevates sympathetic activity in primary hypertension. Hypertension 1994;24:287-96.
25. Zhang W, Sun X, Zhao X, Thoren P, Hedner T. Effects of calcium antagonist felodipine on renal sympathetic nerve activity in rats with congestive heart failure. Cardiovasc Drugs Ther 1997;11:645-50.
26. Palatini P. Heart rate as a risk factor for atherosclerosis and cardiovascular mortality: The effect of antihypertensive drugs. Drugs 1999;57:713-24.
27. Leenen FH, Holliwell DL. Antihypertensive effect of felodipine associated with persistent sympathetic activation and minimal regression of left ventricular hypertrophy. Am J Cardiol 1992;69:639-45.
28. Frishman WH. Impact of calcium antagonists on early morning ischaemia in the patient with coronary disease. Eur Heart J 1999;1:B34-40.
29. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87:VI40-8.
30. Benedict CR, Shelton B, Johnstone DE, et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation 1996;94:690-7.
31. Pahor M, Guralnik JM, Corti MC, Foley DJ, Carbonin P, Havlik RJ. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995;43:1191-7.
32. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 1996;276:785-91.
33. Luft FC, Wilcox CS, Unger T, et al. Angiotensin-induced hypertension in the rat. Sympathetic nerve activity and prostaglandins. Hypertension 1989;14:396-403.
34. Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol 1992;262:E763-78.
35. Bernier NJ, Perry SF. Cardiovascular effects of angiotensin-II-mediated adrenaline release in rainbow trout oncorhynchus mykiss. J Exp Biol 1999;202:55-66.
36. Schofer J, Hobuss M, Aschenberg W, Tews A. Acute and long-term haemodynamic and neurohumoral response to nisoldipine vs captopril in patients with heart failure: A randomized double-blind study. Eur Heart J 1990;11:712-21.
37. DiBona GF, Jones SY, Brooks VL. ANG II receptor blockade and arterial baroreflex regulation of renal nerve activity in cardiac failure. Am J Physiol 1995;269:R1189-96.
38. Zhang W, Huang BS, Leenen FHH. Brain renin-angiotensin system and sympathetic hyperactivity in rats after myocardial infarction. Am J Physiol (Heart Cir Physiol) 1999;45:H1608-15.